Quantcast
Stem Cell Breakthrough Brings Researchers One Step Closer To

Stem Cell Breakthrough Brings Researchers One Step Closer To Type 1 Diabetes Cure

Chuck Bednar for redOrbit.com - Your Universe Online Researchers writing in the October 9 edition of the journal Cell report they have for the first time successfully converted human embryonic stem cells into insulin-producing beta cells...

Latest JDRF Stories

2014-10-15 23:06:04

AAHOA's donation will boost efforts to research and end type 1 diabetes Atlanta, GA (PRWEB) October 15, 2014 The Asian American Hotel Owners Association (AAHOA), the voice of owners in the hospitality industry and a supporter of healthy living, announced today that the organization will donate $5,000 to the Juvenile Diabetes Research Foundation (JDRF) during its Southeast Texas Regional Conference in Houston, Texas. “Southeast Texas is our largest region, and we felt it fitting to...

2014-10-06 16:27:28

NEW YORK, Oct. 6, 2014 /PRNewswire-USNewswire/ -- The Diabetes Research Institute Foundation (DRIF) announced the appointment of Barbara Tavrow as senior vice president. A veteran nonprofit professional with more than 25 years of experience in major gifts fundraising and strategic campaign development, she is profoundly committed to the organization's singular goal of finding a cure for diabetes. http://photos.prnewswire.com/prnvar/20120405/DC83112LOGO "I have been familiar with...

2014-10-06 08:29:21

SAN DIEGO, Oct. 6, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, called VC-01(TM), will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows: -- Dr. Paul Laikind, ViaCyte's President and Chief Executive Officer, is...

2014-09-16 08:31:56

--New Collaboration will Increase Data Available to Artificial Pancreas Researchers -- NEW YORK and SAN FRANCISCO, Sept. 16, 2014 /PRNewswire-USNewswire/ -- JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, and Tidepool (TM), a Silicon Valley-based non-profit organization committed to reducing the burden of T1D, announced a partnership supported by JDRF funding for data access technology for people with T1D who use insulin pumps and...

2014-09-10 16:26:29

SAN DIEGO, Sept. 10, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, called VC-01, announced today that it has been selected to receive a $16.6 million Accelerated Development Pathway Award from the California Institute for Regenerative Medicine (CIRM). According to CIRM, the Accelerated Development Awards were created to "provide selected applicants who are...

2014-09-10 08:29:58

ROSH HA-AYIN, Israel, September 10, 2014 /PRNewswire/ -- Beta-O2 announced today that it has received a $500K grant from JDRF. The grant will be used to help fund a $1M pilot human study of Beta-O2's ssAir bio-artificial pancreas, in development as a treatment and potential cure for type 1 diabetes (T1D). The two-year study, which will enroll eight participants at Uppsala University Hospital in Sweden, will evaluate the safety, survival and function of implanted human islets...

2014-08-26 23:10:27

The Western Pennsylvania Chapter of JDRF has named Susan Manzi, MD, Chair of the Department of Medicine at Allegheny Health Network, corporate chair of its 2014 Walk to Cure Diabetes event in Pittsburgh. Pittsburgh, PA (PRWEB) August 26, 2014 The Western Pennsylvania Chapter of JDRF has named Susan Manzi, MD, Chair of the Department of Medicine at Allegheny Health Network, corporate chair of its 2014 Walk to Cure Diabetes event in Pittsburgh. The JDRF Walk to Cure Diabetes in Pittsburgh...

2014-08-20 08:27:26

SOUTHAMPTON, England, August 20, 2014 /PRNewswire/ -- Phase I Trial of Plasma Kallikrein Inhibitor to be Conducted in the US KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. The study's Principal Investigator is Dr. Jennifer K Sun of the Beetham Eye Institute, Joslin...

2014-08-19 08:30:47

Company Plans to Immediately Initiate Phase 1/2 Clinical Trial SAN DIEGO, Aug. 19, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the U.S. Food and Drug Administration ("FDA") has accepted the company's Investigational New Drug Application ("IND") for its VC-01(TM) candidate cell replacement therapy to treat type 1 diabetes. The company plans to promptly initiate a Phase 1/2 clinical trial which it believes to be the first...

2014-07-30 16:28:55

-- JDRF Calls for CGM Medicare Coverage to Help Improve Health Outcomes Among Seniors with T1D and Advance an Artificial Pancreas -- WASHINGTON, July 30, 2014 /PRNewswire-USNewswire/ -- Today U.S. Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), Co-chairs of the Senate Diabetes Caucus, introduced legislation to ensure that seniors with type 1 diabetes (T1D) who are Medicare eligible have access to continuous glucose monitors (CGM) as prescribed by their physicians. The...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related